{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:51:11Z","timestamp":1791363071818,"version":"4.3.1"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Parasitology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.exppara.2026.109196","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:52:23Z","timestamp":1788533543000},"page":"109196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advances and challenges in novel drug delivery systems for the treatment of leishmaniases: A comprehensive narrative review"],"prefix":"10.1016","volume":"289","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6687-4622","authenticated-orcid":false,"given":"Antara","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exppara.2026.109196_bib1","article-title":"Spanethosomes as a novel topical carrier for silymarin in contrast to conventional spanlastics: formulation development, in vitro and ex vivo evaluation for potential treatment of leishmaniasis","volume":"88","author":"Abd-Alaziz","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.exppara.2026.109196_bib2","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.3390\/molecules26195905","article-title":"Controlled drug delivery systems: current status and future directions","volume":"26","author":"Adepu","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.exppara.2026.109196_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/08982104.2017.1327543","article-title":"Tissue pharmacokinetics and pharmacodynamics of AmBisome (L-AmBis) in uninfected and infected animals and their effects on dosing regimens","volume":"27","author":"Adler-Moore","year":"2017","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.exppara.2026.109196_bib4","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.micpath.2017.07.009","article-title":"Synthesis of phytochemicals-stabilized gold nanoparticles and their biological activities against bacteria and Leishmania","volume":"110","author":"Ahmad","year":"2017","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.exppara.2026.109196_bib6","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.2147\/IJN.S23883","article-title":"Antileishmanial effect of silver nanoparticles and their enhanced antiparasitic activity under ultraviolet light","volume":"6","author":"Allahverdiyev","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.exppara.2026.109196_bib5","doi-asserted-by":"crossref","unstructured":"Almayouf MA, El-Khadragy MF, Awad MA, Al-Olayan EM. The effects of silver nanoparticles 2020. Biosynthesized using fig and olive extracts on cutaneous leishmaniasis induced inflammation in female Balb\/c mice. Biosci. Rep. 40:doi: 10.1042\/BSR20202672.","DOI":"10.1042\/BSR20202672"},{"key":"10.1016\/j.exppara.2026.109196_bib7","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1007\/s13346-022-01127-4","article-title":"Nanotechnological approaches for pentamidine delivery","volume":"12","author":"Andreana","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.exppara.2026.109196_bib8","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2023.2173335","article-title":"Co-delivery of amphotericin B and pentamidine loaded niosomal gel for the treatment of cutaneous leishmaniasis","volume":"30","author":"Anjum","year":"2023","journal-title":"Drug Deliv."},{"issue":"12","key":"10.1016\/j.exppara.2026.109196_bib9","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1086\/518172","article-title":"Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis","volume":"44","author":"Arevalo","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.exppara.2026.109196_bib10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3390\/tropicalmed9090218","article-title":"Tolerability and safety of miltefosine for the treatment of cutaneous leishmaniasis","volume":"9","author":"Astman","year":"2024","journal-title":"Trop. Med. Infect. Dis."},{"key":"10.1016\/j.exppara.2026.109196_bib11","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.4049\/jimmunol.181.2.1386","article-title":"Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses","volume":"181","author":"Banerjee","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.exppara.2026.109196_bib12","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1128\/AAC.00524-10","article-title":"Combination therapy with paromomycin-associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation","volume":"55","author":"Banerjee","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2026.109196_bib13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/38.1.145","article-title":"Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes","volume":"38","author":"Banerjee","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.exppara.2026.109196_bib14","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.3390\/pharmaceutics14122642","article-title":"Development of Ag-ZnO\/AgO nanocomposites effectives for Leishmania braziliensis treatment","volume":"14","author":"Barbosa","year":"2022","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.exppara.2026.109196_bib15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3390\/pharmaceutics12020149","article-title":"Topical amphotericin B semisolid dosage form for cutaneous leishmaniasis: physicochemical characterization, Ex vivo skin permeation and biological activity","volume":"12","author":"Berenguer","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.exppara.2026.109196_bib16","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1021\/acsinfecdis.4c00231","article-title":"Innovating leishmaniasis treatment: a critical chemist's review of inorganic nanomaterials","volume":"10","author":"Bessa","year":"2024","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.exppara.2026.109196_bib17","first-page":"631","article-title":"Leishmaniasis","author":"Boelaert","year":"2014"},{"key":"10.1016\/j.exppara.2026.109196_bib18","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/jac\/dkac351","article-title":"Liposomal amphotericin B\u2014The past","volume":"77","author":"Br\u00fcggemann","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.exppara.2026.109196_bib19","doi-asserted-by":"crossref","first-page":"5289","DOI":"10.2147\/IJN.S140363","article-title":"Nanostructured delivery systems with improved leishmanicidal activity: a critical review","volume":"12","author":"Bruni","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.exppara.2026.109196_bib20","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.exppara.2026.109196_bib21","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/cid\/ciac127","article-title":"AmBisome monotherapy and combination AmBisome-Miltefosine therapy for the treatment of visceral leishmaniasis in patients coinfected with human immunodeficiency virus in India: a randomized open-label, parallel-arm, phase 3 trial","volume":"75","author":"Burza","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.exppara.2026.109196_bib22","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3390\/biomedicines10051203","article-title":"Current development of nano-drug delivery to target macrophages","volume":"10","author":"Cai","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.exppara.2026.109196_bib23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/08982100903015025","article-title":"Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis","volume":"20","author":"Carneiro","year":"2010","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.exppara.2026.109196_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-020-00382-7","article-title":"Sixty years of amphotericin B: an overview of the main antifungal agent used to treat invasive fungal infections","volume":"10","author":"Cavassin","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.exppara.2026.109196_bib25","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4103\/0974-777X.62887","article-title":"Drug resistance in leishmaniasis","volume":"2","author":"Chakravarty","year":"2010","journal-title":"J. Global Infect. Dis."},{"key":"10.1016\/j.exppara.2026.109196_bib26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1017\/S0031182017000993","article-title":"Repurposing as a strategy for the discovery of new anti-leishmanials: The-state-of-the-art","volume":"145","author":"Charlton","year":"2018","journal-title":"Parasitology"},{"key":"10.1016\/j.exppara.2026.109196_bib27","first-page":"e59","article-title":"Exploring the potential of transethosomes in therapeutic delivery: a comprehensive review","volume":"2","author":"Chowdary","year":"2023","journal-title":"MedComm \u2013 Biomater Appl"},{"key":"10.1016\/j.exppara.2026.109196_bib28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4269\/ajtmh.2011.10-0155","article-title":"Randomized controlled clinical trial to access efficacy and safety of Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil","volume":"84","author":"Chrusciak-Talhari","year":"2011","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.exppara.2026.109196_bib29","first-page":"147","article-title":"Renal involvement in leishmaniasis: a review of the literature","volume":"4","author":"Clementi","year":"2011","journal-title":"NDT Plus"},{"key":"10.1016\/j.exppara.2026.109196_bib31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bpc.2016.07.005","article-title":"Miltefosine-loaded lipid nanoparticles: improving miltefosine stability and reducing its hemolytic potential toward erythtocytes and its cytotoxic effect on macrophages","volume":"217","author":"da Gama Bitencourt","year":"2016","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.exppara.2026.109196_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2021.117145","article-title":"Lipid shell lipid nanocapsules as smart generation lipid nanocarriers","volume":"339","author":"Dabholkar","year":"2021","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.exppara.2026.109196_bib32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0885-4505(90)90018-V","article-title":"Targeting of urea stibamine encapsulated in liposomes to reticuloendothelial system for the treatment of experimental leishmaniasis","volume":"43","author":"Das","year":"1990","journal-title":"Biochem. Med. Metab. Biol."},{"key":"10.1016\/j.exppara.2026.109196_bib33","first-page":"6","article-title":"In vitro study on cytotoxic effects of ZnO nanoparticles on promastigote and amastigote forms of Leishmania major (MRHO\/IR\/75\/ER)","volume":"9","author":"Delavari","year":"2014","journal-title":"Iran. J. Parasitol."},{"key":"10.1016\/j.exppara.2026.109196_bib34","first-page":"9","article-title":"Drug development for neglected tropical diseases: bridging the gap in global health","volume":"13","author":"Desouza","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.exppara.2026.109196_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007132","article-title":"Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia","volume":"13","author":"Diro","year":"2019","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.exppara.2026.109196_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004087","article-title":"Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort study","volume":"9","author":"Diro","year":"2015","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.exppara.2026.109196_bib37","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.exppara.2026.109196_bib38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4103\/1319-2442.198159","article-title":"Visceral leishmaniasis in adults with nephropathy","volume":"28","author":"El Jeri","year":"2017","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.exppara.2026.109196_bib39","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jsps.2021.07.015","article-title":"Nanostructured lipid carriers (NLCs) as drug delivery platform: advances in formulation and delivery strategies","volume":"29","author":"Elmowafy","year":"2021","journal-title":"Saudi Pharm. J."},{"issue":"1","key":"10.1016\/j.exppara.2026.109196_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/pharmaceutics15010099","article-title":"Liposomal amphotericin B for treatment of leishmaniasis: from the identification of critical physicochemical attributes to the design of effective topical and oral formulations","volume":"15","author":"Fr\u00e9zard","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.exppara.2026.109196_bib41","first-page":"538","article-title":"Topical treatment for cutaneous leishmaniasis","volume":"3","author":"Garnier","year":"2002","journal-title":"Curr. Opin. Invest. Drugs"},{"issue":"4","key":"10.1016\/j.exppara.2026.109196_bib42","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/jac\/dkm303","article-title":"In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs","volume":"60","author":"Garnier","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.exppara.2026.109196_bib43","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.nano.2015.06.008","article-title":"Targeted delivery of paromomycin in murine infectious diseases through association to nano lipid systems","volume":"11","author":"Gaspar","year":"2015","journal-title":"Nanomedicine"},{"issue":"4","key":"10.1016\/j.exppara.2026.109196_bib44","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/1735-5362.235156","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages","volume":"13","author":"Ghasemiyeh","year":"2018","journal-title":"Res Pharm Sci. Aug"},{"issue":"1","key":"10.1016\/j.exppara.2026.109196_bib45","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4269\/ajtmh.19-0931","article-title":"Combination therapy against Indian visceral leishmaniasis with liposomal Amphotericin B (FungisomeTM) and short-course miltefosine in comparison to miltefosine monotherapy","volume":"103","author":"Goswami","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.exppara.2026.109196_bib46","series-title":"Pathogenesis, Treatment and Prevention of Leishmaniasis","first-page":"141","article-title":"Natural products as a novel source for antileishmanial drug development","author":"Gouri","year":"2021"},{"key":"10.1016\/j.exppara.2026.109196_bib47","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0169-409X(01)00104-1","article-title":"Amphotericin B colloidal dispersion: an improved antifungal therapy","volume":"47","author":"Guo","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.exppara.2026.109196_bib48","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3797\/scipharm.1208-02","article-title":"Transfersomes: a novel vesicular carrier for enhanced transdermal delivery of sertraline: development, characterization, and performance evaluation","volume":"80","author":"Gupta","year":"2012","journal-title":"Sci. Pharm."},{"key":"10.1016\/j.exppara.2026.109196_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/pim.13068","article-title":"Effects of Amphotericin B-Conjugated functionalized carbon nanoparticles in the treatment of cutaneous leishmaniasis","volume":"46","author":"Heidari-Kharaji","year":"2024","journal-title":"Parasite Immunol."},{"issue":"2","key":"10.1016\/j.exppara.2026.109196_bib50","doi-asserted-by":"crossref","DOI":"10.1111\/pim.70002","article-title":"Solid lipid nanoparticles encapsulated with Paromomycin: an effective oral formulation against Leishmania major in mouse model","volume":"47","author":"Heidari-Kharaji","year":"2025","journal-title":"Parasite Immunol."},{"issue":"Suppl. 2","key":"10.1016\/j.exppara.2026.109196_bib51","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1093\/clinids\/22.Supplement_2.S133","article-title":"Lipid formulations of amphotericin B: recent progress and future directions","volume":"22","author":"Hiemenz","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.exppara.2026.109196_bib52","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/ijd.16407","article-title":"Topical liposomal amphotericin B gel treatment for cutaneous leishmaniasis caused by Leishmania major: a double-blind, randomized, placebo-controlled, pilot study","volume":"62","author":"Horev","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.exppara.2026.109196_bib54","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12951-021-00853-0","article-title":"Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight","volume":"19","author":"Jamshaid","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.exppara.2026.109196_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2022.213266","article-title":"Mannosylated imiquimod-terbinafine co-loaded transethosomes for cutaneous leishmaniasis; assessment of its anti-leishmanial potential, in vivo safety and immune response modulation","volume":"145","author":"Jamshaid","year":"2023","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.exppara.2026.109196_bib55","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.3390\/ph16121646","article-title":"Nanostructured lipid carriers as robust systems for lupeol delivery in the treatment of experimental visceral leishmaniasis","volume":"16","author":"Jesus","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.exppara.2026.109196_bib56","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.4269\/ajtmh.2005.73.1005","article-title":"A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India","volume":"73","author":"Jha","year":"2005","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.exppara.2026.109196_bib57","first-page":"335","article-title":"Effects of silver nanoparticle based on ginger extract on Leishmania infantum and Leishmania tropica parasites: in vitro","volume":"79","author":"Karimipour Saryazdi","year":"2024","journal-title":"Arch Razi Inst"},{"key":"10.1016\/j.exppara.2026.109196_bib58","article-title":"Dr. Upendranath brahmachari: the unsung hero of Indian medical research","volume":"16","author":"Kawalkar","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.exppara.2026.109196_bib59","doi-asserted-by":"crossref","DOI":"10.1098\/rsos.220428","article-title":"Macrophage targeting of nitazoxanide-loaded transethosomal gel in cutaneous leishmaniasis","volume":"9","author":"Khalid","year":"2022","journal-title":"R. Soc. Open Sci."},{"key":"10.1016\/j.exppara.2026.109196_bib60","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.xphs.2022.01.010","article-title":"Designing, optimization and characterization of Trifluralin transfersomal gel to passively target cutaneous leishmaniasis","volume":"111","author":"Khan","year":"2022","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.exppara.2026.109196_bib61","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s40262-017-0570-0","article-title":"Clinical pharmacokinetics of systemically administered antileishmanial drugs","volume":"57","author":"Kip","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.exppara.2026.109196_bib62","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3390\/ph16030362","article-title":"Encapsulation: a strategy to deliver therapeutics and bioactive compounds?","volume":"16","author":"Klojdov\u00e1","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.exppara.2026.109196_bib63","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2169\/internalmedicine.4096-19","article-title":"Failure of liposomal-amphotericin B treatment for new world cutaneous leishmaniasis due to Leishmania braziliensis","volume":"59","author":"Kosaka","year":"2020","journal-title":"Intern. Med."},{"key":"10.1016\/j.exppara.2026.109196_bib64","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00436-014-3755-6","article-title":"Comparative transcript expression analysis of miltefosine-sensitive and miltefosine-resistant Leishmania donovani","volume":"113","author":"Kulshrestha","year":"2014","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.exppara.2026.109196_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.1016925","article-title":"Limitations of current chemotherapy and future of nanoformulation-based AmB delivery for visceral leishmaniasis-An updated review","volume":"10","author":"Kumar","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.exppara.2026.109196_bib66","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.2147\/IJN.S196421","article-title":"Synthesis, characterization, and mechanistic studies of a gold nanoparticle-amphotericin B covalent conjugate with enhanced antileishmanial efficacy and reduced cytotoxicity","volume":"14","author":"Kumar","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.exppara.2026.109196_bib67","doi-asserted-by":"crossref","first-page":"85","DOI":"10.31254\/jsir.2014.3114","article-title":"PLGA-PEG encapsulated sitamaquine nanoparticles drug delivery system against Leishmania donovani","volume":"3","author":"Kumar","year":"2014","journal-title":"J Sci Innov Res"},{"key":"10.1016\/j.exppara.2026.109196_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2022.106661","article-title":"Amphotericin B: a drug of choice for Visceral Leishmaniasis","volume":"235","author":"Kumari","year":"2022","journal-title":"Acta Trop."},{"key":"10.1016\/j.exppara.2026.109196_bib69","doi-asserted-by":"crossref","unstructured":"Laniado-Labor\u0131\u0144 R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. 2009. Rev. Iberoam. Micol. 26:223\u2013227. doi: 10.1016\/j.riam.2009.06.003.","DOI":"10.1016\/j.riam.2009.06.003"},{"key":"10.1016\/j.exppara.2026.109196_bib70","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.2147\/IJN.S430877","article-title":"Advancements in macrophage-targeted drug delivery for effective disease management","volume":"18","author":"Liu","year":"2023","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.exppara.2026.109196_bib71","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2147\/DDDT.S447496","article-title":"Advances in nanotechnology for enhancing the solubility and bioavailability of poorly soluble drugs","volume":"18","author":"Liu","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.exppara.2026.109196_bib72","series-title":"Drug Stability for Pharmaceutical Scientists","first-page":"5","article-title":"Principles of drug degradation","author":"Loftsson","year":"2014"},{"key":"10.1016\/j.exppara.2026.109196_bib73","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.3390\/molecules27072313","article-title":"The potential of 2-substituted quinolines as antileishmanial drug candidates","volume":"27","author":"Loiseau","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.exppara.2026.109196_bib74","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1590\/S1678-9946201658068","article-title":"Pancreatic toxicity as an adverse effect induced by meglumine antimoniate therapy in a clinical trial for cutaneous leishmaniasis","volume":"58","author":"Lyra","year":"2016","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"10.1016\/j.exppara.2026.109196_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007373","article-title":"A single dose of antibody-drug conjugate cures a stage 1 model of African trypanosomiasis","volume":"13","author":"MacGregor","year":"2019","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.exppara.2026.109196_bib76","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.3390\/molecules24234222","article-title":"Bixa orellana L. (Bixaceae) and Dysphania ambrosioides (L.) Mosyakin & clemants (Amaranthaceae) essential oils formulated in nanocochleates against Leishmania amazonensis","volume":"24","author":"Mach\u00edn","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.exppara.2026.109196_bib78","doi-asserted-by":"crossref","first-page":"26627","DOI":"10.1021\/acsomega.5c00879","article-title":"Amine-functionalized graphene quantum dots conjugated with Amphotericin B: synthesis, characterization, and in vitro evaluation for visceral leishmaniasis treatment","volume":"10","author":"Madhukar","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.exppara.2026.109196_bib77","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40121-022-00602-2","article-title":"Treatment of cutaneous leishmaniasis and insights into species-specific responses: a narrative review","volume":"11","author":"Madusanka","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.exppara.2026.109196_bib79","first-page":"140","article-title":"The characterization and antileishmanial evaluation on Leishmania major with Chitosan\/Zno Bio-Nanocomposite as drug delivery systems","volume":"7","author":"Mahmoudi","year":"2022","journal-title":"Nano Res. J"},{"key":"10.1016\/j.exppara.2026.109196_bib80","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1051\/parasite\/2025009","article-title":"Leishmaniases: strategies in treatment development","volume":"32","author":"Majoor","year":"2025","journal-title":"Parasite"},{"key":"10.1016\/j.exppara.2026.109196_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2023.106846","article-title":"A review on new natural and synthetic anti-leishmanial chemotherapeutic agents and current perspective of treatment approaches","volume":"240","author":"Majumder","year":"2023","journal-title":"Acta Trop."},{"key":"10.1016\/j.exppara.2026.109196_bib82","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1590\/abd1806-4841.20198388","article-title":"American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure","volume":"94","author":"Marques","year":"2019","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.exppara.2026.109196_bib83","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/microorganisms8111803","article-title":"Evaluation of a new topical treatment for the control of cutaneous leishmaniasis","volume":"8","author":"Mart\u00ednez-Salazar","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.exppara.2026.109196_bib84","article-title":"A review of current treatments strategies based on paromomycin for leishmaniasis","volume":"57","author":"Matos","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.exppara.2026.109196_bib85","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10856-018-6122-9","article-title":"Reduction toxicity of Amphotericin B through loading into a novel nanoformulation of anionic linear globular dendrimer for improve treatment of leishmania major","volume":"29","author":"Mehrizi","year":"2018","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"10.1016\/j.exppara.2026.109196_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108942","article-title":"Niosomal formulation of amphotericin B alone and in combination with glucantime: in vitro and in vivo leishmanicidal effects","volume":"116","author":"Mostafavi","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.exppara.2026.109196_bib87","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art","volume":"50","author":"M\u00fcller","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.exppara.2026.109196_bib89","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.2147\/IJN.S105195","article-title":"Annihilation of Leishmania by daylight responsive ZnO nanoparticles: a temporal relationship of reactive oxygen species-induced lipid and protein oxidation","volume":"11","author":"Nadhman","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.exppara.2026.109196_bib88","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.freeradbiomed.2014.09.005","article-title":"PEGylated silver doped zinc oxide nanoparticles as novel photosensitizers for photodynamic therapy against Leishmania","volume":"77","author":"Nadhman","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.exppara.2026.109196_bib90","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1049\/iet-nbt.2015.0015","article-title":"Photo-induced Leishmania DNA degradation by silver-doped zinc oxide nanoparticle: an in-vitro approach","volume":"10","author":"Nadhman","year":"2016","journal-title":"IET Nanobiotechnol."},{"key":"10.1016\/j.exppara.2026.109196_bib91","doi-asserted-by":"crossref","first-page":"11305","DOI":"10.1021\/cr500365f","article-title":"Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis","volume":"114","author":"Nagle","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.exppara.2026.109196_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117109","article-title":"Enhancing the efficacy of fluconazole against Leishmania major: formulation and evaluation of FLZ-nanoemulsions for topical delivery","volume":"178","author":"Nahanji","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.exppara.2026.109196_bib94","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.actatropica.2018.05.002","article-title":"Investigation of anti-leishmanial efficacy of miltefosine and ketoconazole loaded on nanoniosomes","volume":"185","author":"Nazari-Vanani","year":"2018","journal-title":"Acta Trop."},{"key":"10.1016\/j.exppara.2026.109196_bib95","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.2147\/IJN.S203351","article-title":"Antileishmanial activity and cytotoxicity of ZnO-based nano-formulations","volume":"14","author":"Nazir","year":"2019","journal-title":"Int. J. Nanomed."},{"issue":"Suppl. 1","key":"10.1016\/j.exppara.2026.109196_bib96","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1097\/QAI.0000000000000037","article-title":"Regulatory challenges associated with conducting multicountry clinical trials in resource-limited settings","volume":"65","author":"Ndebele","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.exppara.2026.109196_bib97","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.idcr.2014.07.003","article-title":"Cutaneous leishmaniasis with atypical clinical manifestations: case report","volume":"1","author":"Neitzke-Abreu","year":"2014","journal-title":"IDCases"},{"key":"10.1016\/j.exppara.2026.109196_bib98","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-60883-0","article-title":"Preparation and characterization of artemether-loaded niosomes in Leishmania major-induced cutaneous leishmaniasis","volume":"14","author":"Niroumand","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.exppara.2026.109196_bib99","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3390\/pharmaceutics14071499","article-title":"Efficacy and safety of topical morphine: a narrative review","volume":"14","author":"Nosek","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.exppara.2026.109196_bib100","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.actatropica.2011.02.007","article-title":"Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World","volume":"118","author":"Oliveira","year":"2011","journal-title":"Acta Trop."},{"key":"10.1016\/j.exppara.2026.109196_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106459","article-title":"An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis","volume":"59","author":"Pali\u0107","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.exppara.2026.109196_bib102","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.4269\/ajtmh.17-0094","article-title":"Efficacy and safety of liposomal Amphotericin B for visceral leishmaniasis in children and adolescents at a tertiary care center in Bihar, India","volume":"97","author":"Pandey","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.exppara.2026.109196_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fnano.2021.665274","article-title":"Nano based approach for the treatment of neglected tropical diseases","volume":"3","author":"Pandian","year":"2021","journal-title":"Front. Nanotechnol."},{"key":"10.1016\/j.exppara.2026.109196_bib104","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3347\/kjp.2019.57.4.359","article-title":"Antileishmanial activity of niosomal combination forms of tioxolone along with benzoxonium chloride against Leishmania tropica","volume":"57","author":"Parizi","year":"2019","journal-title":"Kor. J. Parasitol."},{"issue":"1","key":"10.1016\/j.exppara.2026.109196_bib105","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-69276-5","article-title":"Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis","volume":"10","author":"Parvez","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.exppara.2026.109196_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.570573","article-title":"Recuperating biopharmaceutical aspects of Amphotericin B and paromomycin using a chitosan functionalized nanocarrier via oral route for enhanced anti-leishmanial activity","volume":"10","author":"Parvez","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.exppara.2026.109196_bib107","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s13346-021-00896-8","article-title":"Efficacy of topical Miltefosine formulations in an experimental model of cutaneous leishmaniasis","volume":"12","author":"Peralta","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.exppara.2026.109196_bib108","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8629039","article-title":"Efficacy and safety of paromomycin for visceral leishmaniasis: a systematic review","volume":"2021","author":"Pokharel","year":"2021","journal-title":"J. Trop. Med."},{"key":"10.1016\/j.exppara.2026.109196_bib109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006052","article-title":"Drug resistance and treatment failure in leishmaniasis: a 21st century challenge","volume":"11","author":"Ponte-Sucre","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.exppara.2026.109196_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111920","article-title":"Current status of nanoscale drug delivery and the future of nano-vaccine development for leishmaniasis - a review","volume":"141","author":"Prasanna","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.exppara.2026.109196_bib111","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1128\/AAC.00030-11","article-title":"Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani","volume":"56","author":"Purkait","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2026.109196_bib113","doi-asserted-by":"crossref","first-page":"623","DOI":"10.4103\/1735-5362.327508","article-title":"Artemether-loaded nanostructured lipid carriers: preparation, characterization, and evaluation of in vitro effect on Leishmania major","volume":"16","author":"Rahnama","year":"2021","journal-title":"Res. Pharm. Sci."},{"key":"10.1016\/j.exppara.2026.109196_bib112","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2217\/fmb-2021-0094","article-title":"Potential molecular targets of Leishmania pathways in developing novel antileishmanials","volume":"17","author":"Ramu","year":"2022","journal-title":"Future Microbiol."},{"issue":"1","key":"10.1016\/j.exppara.2026.109196_bib114","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/ALN.0b013e31817b5ac3","article-title":"Temporal effects of topical morphine application on cutaneous wound healing","volume":"109","author":"Rook","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1016\/j.exppara.2026.109196_bib115","series-title":"Principles and Practice of Pediatric Infectious Diseases","first-page":"1567","article-title":"Antiparasitic agents","author":"Ryan","year":"2018"},{"key":"10.1016\/j.exppara.2026.109196_bib116","first-page":"245","article-title":"Immune responses in kala-azar","volume":"123","author":"Saha","year":"2006","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.exppara.2026.109196_bib117","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/pharmaceutics16010041","article-title":"Solid lipid nanoparticles enhancing the leishmanicidal activity of delamanid","volume":"16","author":"Santamar\u00eda-Aguirre","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.exppara.2026.109196_bib118","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.3390\/nano10061152","article-title":"Amphotericin B loaded polymeric nanoparticles for treatment of Leishmania infections","volume":"10","author":"Saqib","year":"2020","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.exppara.2026.109196_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2023.130416","article-title":"4',7-dihydroxyflavone conjugated carbon nanotube formulation demonstrates improved efficacy against Leishmania parasite","volume":"1867","author":"Sasidharan","year":"2023","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.exppara.2026.109196_bib120","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.parint.2014.07.008","article-title":"Carbon nanotube based betulin formulation shows better efficacy against Leishmania parasite","volume":"63","author":"Saudagar","year":"2014","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.exppara.2026.109196_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.1000972","article-title":"Leishmaniasis and Chagas disease: is there hope in nanotechnology to fight neglected tropical diseases?","volume":"12","author":"Scariot","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.exppara.2026.109196_bib122","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0035-9203(99)90192-X","article-title":"Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis","volume":"93","author":"Schmidt-Ott","year":"1999","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.exppara.2026.109196_bib123","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0924-8579(03)00125-0","article-title":"Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine)","volume":"22","author":"Seifert","year":"2003","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.exppara.2026.109196_bib124","first-page":"258","article-title":"Topical therapy of acute cutaneous leishmaniasis using zinc sulphate solution 25% versus podophyllin solution 25%","volume":"7","author":"Sharquie","year":"2017","journal-title":"J. Chem. Dermatol. Sci. Appl."},{"key":"10.1016\/j.exppara.2026.109196_bib125","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40249-016-0112-2","article-title":"Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective","volume":"5","author":"Singh","year":"2016","journal-title":"Infect. Dis. Poverty"},{"key":"10.1016\/j.exppara.2026.109196_bib126","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11095-017-2293-1","article-title":"Fabrication of 3-O-sn-Phosphatidyl-L-serine anchored PLGA nanoparticle bearing Amphotericin B for macrophage targeting","volume":"35","author":"Singh","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.exppara.2026.109196_bib127","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/pathogens12050706","article-title":"Recent advances in chemotherapeutics for leishmaniasis: importance of the cellular biochemistry of the parasite and its molecular interaction with the host","volume":"12","author":"Singh","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.exppara.2026.109196_bib128","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13071-017-1969-z","article-title":"Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India","volume":"10","author":"Srivastava","year":"2017","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.exppara.2026.109196_bib129","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1086\/318121","article-title":"Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic","volume":"31","author":"Sundar","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.exppara.2026.109196_bib131","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/cid\/cis474","article-title":"Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use","volume":"55","author":"Sundar","year":"2012","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.exppara.2026.109196_bib132","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/21678707.2024.2335248","article-title":"Current and emerging therapies for the treatment of leishmaniasis","volume":"12","author":"Sundar","year":"2024","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.exppara.2026.109196_bib130","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4269\/ajtmh.2011.10-0409","article-title":"Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India","volume":"84","author":"Sundar","year":"2011","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.exppara.2026.109196_bib133","first-page":"38","article-title":"In vitro and in vivo evaluation of essential oil from Artemisia absinthium L. formulated in nanocochleates against cutaneous leishmaniasis","volume":"4","author":"Tamargo","year":"2017","journal-title":"Medicines (Basel)"},{"key":"10.1016\/j.exppara.2026.109196_bib134","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1021\/acsinfecdis.4c00010","article-title":"Revolutionizing leishmaniasis treatment with cutting edge drug delivery systems and nanovaccines: an updated review","volume":"10","author":"Tambe","year":"2024","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.exppara.2026.109196_bib135","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/08982104.2020.1749067","article-title":"Use of liposomal nanoformulations in antileishmania therapy: challenges and perspectives","volume":"31","author":"T\u00e9llez","year":"2021","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.exppara.2026.109196_bib136","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0168-3659(99)00222-9","article-title":"Ethosomes--novel vesicular carriers for enhanced delivery: characterization and skin penetration properties","volume":"65","author":"Touitou","year":"2000","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.exppara.2026.109196_bib137","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1007\/s00436-022-07659-5","article-title":"Liposomal drug delivery systems for the treatment of leishmaniasis","volume":"121","author":"Tuon","year":"2022","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.exppara.2026.109196_bib138","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.2174\/0929867331666230823094737","article-title":"PLGA nanoparticles as new drug delivery systems in leishmaniasis chemotherapy: a review of current practices","volume":"31","author":"Valiallahi","year":"2024","journal-title":"Curr. Med. Chem."},{"issue":"5","key":"10.1016\/j.exppara.2026.109196_bib139","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02419-17","article-title":"Topical treatment for cutaneous leishmaniasis: dermato-pharmacokinetic lead optimization of benzoxaboroles","volume":"62","author":"Van Bocxlaer","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2026.109196_bib140","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/jphp.12548","article-title":"Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB\/c mouse model","volume":"68","author":"Van Bocxlaer","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.exppara.2026.109196_bib141","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1473-3099(10)70011-6","article-title":"Combination therapy for visceral leishmaniasis","volume":"10","author":"van Griensven","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.exppara.2026.109196_bib142","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1016\/S1473-3099(23)00353-5","article-title":"The status of combination therapy for visceral leishmaniasis: an updated review","volume":"24","author":"van Griensven","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.exppara.2026.109196_bib143","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1021\/acsbiomaterials.0c01132","article-title":"Nano- and microformulations to advance therapies for visceral leishmaniasis","volume":"7","author":"Varma","year":"2021","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.exppara.2026.109196_bib144","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3390\/pharmaceutics12100915","article-title":"Mannose-decorated dendritic polyglycerol nanocarriers drive antiparasitic drugs to Leishmania infantum-infected macrophages","volume":"12","author":"Vossen","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.exppara.2026.109196_bib145","doi-asserted-by":"crossref","DOI":"10.35500\/jghs.2020.2.e3","article-title":"Visceral leishmaniasis: a global overview","volume":"2","author":"Wamai","year":"2020","journal-title":"J. Glob. Health. Sci."},{"key":"10.1016\/j.exppara.2026.109196_bib146","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.2147\/IJN.S268548","article-title":"Critical antileishmanial in vitro effects of highly examined gold nanoparticles","volume":"16","author":"Want","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.exppara.2026.109196_bib147","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.3390\/pharmaceutics14112316","article-title":"Review of novel oral Amphotericin B formulations for the treatment of parasitic infections","volume":"14","author":"Wasan","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.exppara.2026.109196_bib148","doi-asserted-by":"crossref","first-page":"871","DOI":"10.4269\/ajtmh.2005.73.871","article-title":"A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya","volume":"73","author":"Wasunna","year":"2005","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.exppara.2026.109196_bib152","doi-asserted-by":"crossref","unstructured":"Wiwanitkit V. Interest in paromomycin for the treatment of visceral leishmaniasis (Kala-azar). 2012. Therapeut. Clin. Risk Manag. 8, 323\u2013328. doi: 10.2147\/TCRM.S30139.","DOI":"10.2147\/TCRM.S30139"},{"key":"10.1016\/j.exppara.2026.109196_bib153","article-title":"Immunotherapy and immunochemotherapy in combating visceral leishmaniasis","volume":"10","author":"Yadagiri","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.exppara.2026.109196_bib154","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fmolb.2020.00193","article-title":"Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance","volume":"7","author":"Yao","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.exppara.2026.109196_bib155","doi-asserted-by":"crossref","first-page":"7593","DOI":"10.2147\/IJN.S220410","article-title":"Comparative analysis between four model nanoformulations of amphotericin B-chitosan, amphotericin B-dendrimer, betulinic acid-chitosan and betulinic acid-dendrimer for treatment of Leishmania major: real-time PCR assay plus","volume":"14","author":"Zadeh Mehrizi","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.exppara.2026.109196_bib156","article-title":"Progress in antileishmanial drugs: mechanisms, challenges, and prospects","volume":"19","author":"Zhang","year":"2025","journal-title":"PLoS Neglected Trop. Dis."}],"container-title":["Experimental Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014489426001037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014489426001037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:07:03Z","timestamp":1791360423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014489426001037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":152,"alternative-id":["S0014489426001037"],"URL":"https:\/\/doi.org\/10.1016\/j.exppara.2026.109196","relation":{},"ISSN":["0014-4894"],"issn-type":[{"value":"0014-4894","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances and challenges in novel drug delivery systems for the treatment of leishmaniases: A comprehensive narrative review","name":"articletitle","label":"Article Title"},{"value":"Experimental Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exppara.2026.109196","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109196"}}